350 rub
Journal Technologies of Living Systems №2 for 2013 г.
Article in number:
Epidermal growth factor receptors and their ligancds in malignant tumours: significance and prospects in clinic
Keywords: epidermal growth factor receptors EGFR ligands general and relapse free survival antitumour target therapy
Authors:
O.I. Kostyleva, E.S. Gershtein
Abstract:
The review of literature data and the own results of investigations of EGFR and their ligand significance in malignancies pathogenesis and metastasizing and of their relationships with clinico-morphological characteristics, and also of their influence on general and relapse free survival in patients with different cancers are presented. 598 patients with malignant and benign tumours were investigated: 291 breast cancer patients, 44 ovarian cancer and 12 benign ovarian tumours, 58 endometrial cancers and 31 patietms with hyperplastic endometrial processes, and also 115 patients with bone tumours and tumour-like bone lesions. A general tendency to increasing of EGFR+ tumours phenotype with the growth of malignancy grade was established in different cancers. Complex investigation of EGFR and estrogen and progesterone receptors was recommended in breast cancer patients, because of auto/paracrine tumour phenotype is reliable factor of poor prognosis for breast cancer (p<0,03). And also EGFR and their ligands are significant prognosis factors in non small cell lung cancer. EGFR investigation is important for successful antiEGFR target therapy.
Pages: 50-65
References
  1. Герштейн Е.С., Бочарова Л.Б. Ермилова В.Д., Лактионов К.П., Кушлинский Н.Е. Рецепторы эпидермального фактора роста и их лиганды в карциномах эндометрия: связь с клинико-морфологическими факторами и рецепторами стероидов // Вопросы онкологии. 2000. Т. 46, № 2. С. 180 - 186.
  2. Герштейн Е.С., Бочарова Л.Б., Кушлинский Н.Е. Роль РЭФР-зависимого пути передачи митогенных сигналов в регуляции пролиферации эндометрия в норме и при опухолевых процессах // Новое в онкологии. Сб. научных трудов. Воронеж. 2000. Вып. 4. С. 158 - 170.
  3. Герштейн Е.С., Кушлинский Н.Е. Изучение механизмов передачи митогенных сигналов факторов роста как основа для создания и использования противоопухолевых препаратов // Новое в онкологии. Сб. научных трудов. Вып. 3. 1998. С. 126 - 149.
  4. Герштейн Е.С., Кушлинский Н.Е. Современные представления о механизмах передачи сигналов факторов роста как основа эффективной молекулряно-направленной противоопухолевой терапии // Вопросы биологической, медицинской фармацевтической химии. 2007. № 1. С. 4 - 9.
  5. Герштейн Е.С., Кушлинский Н.Е., Давыдов М.И. Рецепторы семейства c-ErbB как мишени молекулярно-направленной противоопухолевой терапии: достижения, проблемы, перспективы // Молекулярная медицина. 2010. № 4. С. 5 - 10.
  6. Герштейн Е.С., Кушлинский Н.Е., Дворова Е.К. и др. Рецепторы эпидермального фактора роста и их лиганды как молекулярные маркеры прогноза и гормоночувствительности рака молочной железы // Клиническая лабораторная диагностика. 1998. № 2. С. 9 - 13.
  7. Дыхно А.Ю., Костылева О.И., ГерштейнЕ.С. идр.Рецепторы эпидермального фактора роста и их лиганды при немелкоклеточном раке легкого // Вестник РАМН. 1998. № 5. С. 51 - 54.
  8. Костылева О.И., Герштейн Е.С., Дыхно А.Ю. и др. Клиническое и прогностическое значение экспрессии рецепторов эпидермального фактора роста при немелкоклеточном раке легкого // Бюллетень экспериментальной биологии и медицины. 1999. Т. 127. № 4. С. 64 - 67.
  9. Костылева О.И., Герштейн Е.С., Радченко А.А. и др. Клиническое значение рецепторов эпидермального фактора роста и их лигандов при остеогенной саркоме // Вопросы биологической медицинской фармацевтической химии. 1998. № 1. С. 30 - 34.
  10. Костылева О.И., Кушлинский Н.Е. Локальные регуляторы роста клеток костной и хрящевой тканей в норме и при бластомогенезе // Вестник ОНЦ АМН России. 1997. № 1. С. 33 - 41.
  11. Кушлинский Н.Е., Герштейн Е.С., Шатская В.А. и др. Современные направления в изучении биохимических критериев гормональной чувствительности рака молочной железы // Вестник ОНЦ АМН России. 1994. № 1. С. 17 - 22.
  12. Кушлинский Н.Е., Костылева О.И., Радченко А.А. и др. Рецепторы эпидермального фактора роста, эстрогенов и глюкокортикоидов в первичных опухолях костей // Вестник ОНЦ АМН России. 1996. № 1. С. 20 - 26.
  13. Кушлинский Н.Е., Костылева О.И., Радченко А.А. и др.Рецепторы эпидермального фактора роста и эстрогенов в первичных опухолях костей // Бюллетень экспериментальной биологии и медицины. 1996. № 7. С. 78-82.
  14. Сметник В.П., Чернуха Г.Е., Герштейн Е.С. и др. Рецепторы эпидермального фактора роста при аденоматозе эндометрия // Бюлл. Экспер. Биол. Мед. 1999. № 1. С. 45-49.
  15. Шарашенидзе О.А., Костылева О.И., Манухин И.Б. и др.Исследование рецепторов эпидермального фактора роста и их лигандов при новообразованиях яичников // Вопросы биологической, медицинской фармацевтической химии. 2012. № 10. С. 26-29.
  16. Adams C.W., Allison D.E., Flagella K. et al.Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab // Cancer Immunol. Immunother. 2006. V. 55. № 6. P. 717 - 727.
  17. Ahmed N., Salsman V.S., Yvon E. et al. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression // Mol. Ther. 2009. V. 17. № 10. P. 1779 - 1787.
  18. Agus D.B., Gordon M.S., Taylor C. et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer // J. Clin. Oncol. 2005. V. 23. № 11. P. 2534 - 2543.
  19. Anido J., Matar P., Albanell J. et al. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells // Clin. Cancer Res. 2003. V. 9. № 4. P. 1274 - 1283.
  20. Badache A., Hynes N.E. A new therapeutic antibody masks ErbB2 to its partners // Cancer Cell. 2004. V. 5. № 4. P. 299 - 301.
  21. Burtness B. The role of cetuximab in the treatment of squamous cell cancer of the head and neck // Expert. Opin. Biol. Ther. 2005. V. 5. № 8. P. 1085 - 1093.
  22. Barnard J.A., Graves D.R., Pittelkow M.R. et al. Auto-and crossinduction withib the mammalian epidermal growth factor related peptide family // J. Biol. Chem. 1994. № 269. P. 22817 - 22822.
  23. Benraad T.J., Foekens J.A. Hydroxylapatite assay to measure epidermal growth factor receptor in human primary breast tumors // Ann. Clin. Biochem. 1990. V. 27. P. 272 - 273.
  24. Castillo L., Etienne-Grimaldi M.C., Fischel J.L. et al.Pharmacological background of EGFR targeting // Ann. Oncol. 2004. V. 15. № 7. P. 1007 - 1012.
  25. Chan C.T., Metz M.Z., Kane S.E. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors // Breast Cancer Res. Treat. 2005. V. 91. № 2. P. 187 - 201.
  26. Chantry A. The kinase domain and membrane localization determine intracellular interactions between epidermal growth factor receptors // J. Biol. Chem. 1995. V. 270. P. 3068 - 3073.
  27. Cho H.S., Mason K., Ramyar K.X. et al.Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab // Nature. 2003. V. 421. № 6924. P. 756 - 760.
  28. Chung K.Y., Shia J., Kemeny N.E. et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry // J. Clin. Oncol. 2005. V. 23. № 9. P. 1803 - 1810.
  29. Cuello M., Ettenberg S.A., Clark A.S. et al.Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2 // Cancer Res. 2001. V. 61. № 12. P. 4892 - 4900.
  30. Diermeier S., Horvath G., Knuechel-Clarke R. et al. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation // Exp. Cell. Res. 2005. V. 304. № 2. P. 604 - 619.
  31. Dillman R.O. Perceptions of Herceptin: a monoclonal antibody for the treatment of breast cancer // Cancer Biother. Radiopharm. 1999. V. 14. № 1. P. 5 - 10.
  32. Fedi P., Tronick S.R., Aaronson S.A. Growth factors. In: Cancer Med., Fourth Edition, edts. J. Holland, R.C.Bast, D.L.Murton. Williams &Wilkins. 1997. P. 41 - 64.
  33. Fischel J.L., Formento P., Milano G. Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors // Br. J. Cancer. 2005. V. 92. № 6. P. 1063 - 1068.
  34. Franklin M.C., Carey K.D., Vajdos F.F. et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex // Cancer Cell. 2004. V. 5. № 4. P. 317 - 328.
  35. Friess T., Scheuer W., Hasmann M. Combi­nation treatment with erlotinib and pertu­zumab against human tumor xenografts is superior to monotherapy // Clin. Cancer Res. 2005. V. 11. № 14. P. 5300 - 5309.
  36. Frieze D.A., McCune J.S. Current status of cetuximab for the treatment of patients with solid tumors // Ann. Pharmacother. 2006. V. 40. № 2. P. 241 - 250.
  37. Gershtein E.S., Shatskaya V.A., Kostyleva O.I. et al. Comparative analysis of the sensitivity of endometrial cancer cells to epidermal growth factor and steroid hormones // Cancer. 1995. V. 76. № 12. P. 2524 - 2529.
  38. Harari P.M. Epidermal growth factor receptor inhibition strategies in oncology // Endocr. Relat. Cancer. 2004. V. 11. № 4. P. 689 - 708.
  39. Henson E.S., Hu X., Gibson S.B. Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression // Clin. Cancer Res. 2006. V. 12 (3 Pt. 1). P. 845 - 853.
  40. Huang S., Armstrong E.A., Benavente S. et al. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor // Cancer Res. 2004. V. 64, № 15. P. 5355 - 5362.
  41. Huang H.-J.S., Nagane M., Klingbeil C.K. et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptors common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unaltered signaling // J. Biol. Chem. 1997. V. 272. Р. 2927 - 2935.
  42. Hsuan J.J. Oncogene regulation by growth factors // Anticancer Res. 1993. V. 13. P. 2521 - 2522.
  43. Izumi Y., Xu L., di Tomaso E. et al. Tumour biology: herceptin acts as an anti-angiogenic cocktail // Nature. 2002. V. 416. № 6878. P. 279 - 280.
  44. Janmaat M.L., Kruyt F.A., Rodriguez J.A., Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways // Clin. Cancer Res. 2003. V. 9. № 6. P. 2316 - 2326.
  45. Kaufmann Z.A., Klinger R., Endemann G. et al. Regulation of human type II phosphatidylinositol kinase activity by epidermal growth factor dependent phosphorylation andreceptor assotiation // J. Biol. Chem. 1994. V. 269. P. 31243 - 31251.
  46. Kauraniemi P., Hautaniemi S., Autio R. et al. Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines // Oncogene. 2004. V. 23. № 4. P.1010 - 1013.
  47. Klippel A., Reinhard C., Kavanaugh W.M. et al. Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple receptor turosine kinases // J. Biol. Chem. 1996. V. 271. Р. 748 - 754.
  48. Kute T., Lack C.M., Willingham M. et al. Development of Herceptin resistance in breast cancer cells // Cytometry A. 2004. V. 57. № 2. P. 86 - 93.
  49. Langer C.J. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC // Int. J. Radiat. Oncol. Biol. Phys. 2004. V. 58. № 3. P. 991 - 1002.
  50. Lee S., Yang W., Lan K.H. et al. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells // Cancer Res. 2002. V. 62. № 20. P. 5703 - 5710.
  51. Le Jeune S., Leek R., Horak Е. et al. Amphiregulin, epidermal growth factor receptorm and estrogen receptor expression in human primary breast cancer // Cancer Res. 1993. V. 53. P. 3597 - 3602.
  52. Lu Y., Zi X., Pollak M. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells // Int. J. Cancer. 2004. V. 108. № 3. P. 334 - 341.
  53. Lu Y., Zi X., Zhao Y. et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin) // J. Natl. Cancer Inst. 2001. V. 93. № 24.  P. 1852 - 1857.
  54. Luwor R.B., Lu Y., Li X. et al. The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression // Oncogene. 2005. V. 24. № 27. P. 4433 - 4441.
  55. Marches R., Uhr J.W. Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells // Int. J. Cancer. 2004. V. 112. № 3. P. 492 - 501.
  56. Matar P., Rojo F., Cassia R. et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting // Clin. Cancer Res. 2004. V. 10. № 19. P. 6487 - 6501.
  57. Mayfield S., Vaughn J.P., Kute T.E. DNA strand breaks and cell cycle perturbation in herceptin treated breast cancer cell lines // Breast Cancer Res. Treat. 2001. V. 70. № 2. P. 123 - 129.
  58. Mendelsohn J., Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer // J. Clin. Oncol. 2003. V. 21. № 14.
    P. 2787 - 2799.
  59. Miyamoto S., Hirata M., Yamazaki A. et al.Heparin-Binding EGF-Like Growth Factor Is a Promising Target for Ovarian Cancer Therapy // Cancer Res. 2004. V. 64. P. 5720 - 5727.
  60. Mocanu M.M., Fazekas Z., Petras M. et al. Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines // Cancer Lett. 2005. V. 227. № 2. P. 201 - 212.
  61. Moghal N., Sternberg P.W. Multiple positive and negative regulators of signaling by the EGF-receptor // Curr. Opin. Cell Biol. 1999. V. 11. № 2. P. 190 - 196.
  62. Molina M.A., Codony-Servat J., Albanell J. et al.Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells // Cancer Res. 2001. V. 61. № 12. P. 4744 - 4749.
  63. Moscatello D.K., Montgomery R.B., Sundaresha P. et al. Transformation and altered signal transduction by a naturally occurring mutant EGF receptor // Oncogene. 1996.№ 13.Р. 85 - 96.
  64. Murray S. Trastuzumab (Herceptin) and HER2-positive breast cancer // Cmaj.2006. V. 174. № 1. P. 36 - 37.
  65. Nagy P., Friedlander E., Tanner M. et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line // Cancer Res. 2005. V. 65. № 2. P. 473 - 482.
  66. Nahta R., Esteva F.J. Herceptin: mechanisms of action and resistance // Cancer Lett. 2006. V. 232. №2.  P. 123 - 138.
  67. Nahta R., Hung M.C., Esteva F.J. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells // Cancer Res. 2004. V. 64. № 7. P. 2343 - 2346.
  68. Nakamura H., Takamori S., Fujii T. et al. Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer // Cancer Lett. 2005. V. 230.  № 1. P. 33 - 46.
  69. Nesterov A., Kurten R.C., Gill G.N. Association of epidermal growth factor receptors with coated pit adaptins via a tyrosine phosphorylation-regulated mechanism // J. Biol. Chem. 1995. № 270. Р.6320-6327. 
  70. Nicholson R.I.,Gee J.M.,Harper M.E. EGFR and cancer prognosis // Eur. J. Cancer. 2001. V. 37. № 4. P.9 - 15.
  71. Normanno N., Campiglio M., De L.A. et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth // Ann. Oncol. 2002. V. 13. № 1. P. 65 - 72.
  72. Normanno N., Ciardiello F., Brandt R. et al. Epidermal growth factor-related peptides in the pathogenesis of human breast cancer // Breast Cancer Res. Treat. 1994. V. 29. P. 11 - 27.
  73. Plosker G.L., Keam S.J. Trastuzumab: A Review of its Use in the Management of HER2-Positive Metastatic and Early-Stage Breast Cancer // Drugs. 2006. V. 66. № 4. P. 449 - 475.
  74. Prewett M., Rockwell P., Rockwell R.F. et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma // J. Immunother. Emphasis. Tumor Immunol. 1996. V. 19. № 6.  P. 419 - 427.
  75. Price-Schiavi S.A., Jepson S., Li P. et al.Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance // Int. J. Cancer. 2002. V. 99. № 6. P. 783 - 791.
  76. Raymond E., Faivre S., Armand J.P. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy // Drugs.-2000. V. 60, Suppl 1.  P. 15 - 23; discussion 41 - 12.
  77. Reese D.M., Slamon D.J. HER-2/neu signal transduction in human breast and ovarian cancer // Stem Cells. 1997. № 15. P. 1 - 8.
  78. Schelissinger J. The epidermal growth factor receptor as a multifunctional allosteric protein // Biochemistry. 1988. № 27. P. 3119 - 3123.
  79. Silvestri G.A., Rivera M.P. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists // Chest. 2005. V. 128. № 6. P. 3975 - 3984.
  80. Sliwkowski M.X., Lofgren J.A., Lewis G.D. et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin) // Semin. Oncol. 1999. V. 26 (4 Suppl. 12). P. 60 - 70.
  81. Smith B.L., Chin D., Maltzman W. et al. The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins // Br. J. Cancer. 2004. V. 91. № 6. P. 1190 - 1194.
  82. Sweeb R.K., Beinjen J.H. Signal transduction pathways, new targets in oncology// Pharm.World Sci. 1993. V. 15. P. 233 - 242.
  83. Talukder A.H., Bagheri-Yarmand R., Williams R.R. et al. Antihuman epidermal growth factor receptor 2 antibody herceptin inhibits autocrine motility factor (AMF) expression and potentiates antitumor effects of AMF inhibitors // Clin. Cancer Res. 2002. V. 8. № 10. P. 3285 - 3289.
  84. Tanner M., Kapanen A.I., Junttila T. et al. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer // Mol. Cancer Ther. 2004. V. 3. № 12. P. 1585 - 1592.
  85. Tiseo M., Loprevite M., Ardizzoni A. Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer // Curr. Med. Chem. Anticancer Agents. 2004. V. 4. № 2. P. 139 - 148.
  86. Travis W.D., Brambilla E., Noguchi M. еt al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma // J. Thorac. Oncol. 2011. V. 6. № 2. Р. 244 - 285.
  87. Vallbohmer D., Zhang W., Gordon M. et al. Molecular determinants of cetuximab efficacy // J. Clin. Oncol. 2005. V. 23. № 15. P. 3536 - 3544.
  88. Voldborg B.R., Damstrup L., Spang-Thomsen M., Poulsen H.S. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials // Ann. Oncol. 1997. № 8. P. 1197 - 1206.
  89. Walshe J.M., Denduluri N., Berman A.W. et al. A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer // Clin. Breast Cancer. 2006. V. 6. № 6. P. 535 - 539.
  90. Whitman M., Cantley L. Phosphoinositide metabolism and control of cell proliferation // Biochim. Biophys. Acta. 1988. V. 948. P. 327 - 344.
  91. Wild R., Fager K., Flefleh C. et al. Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels // Mol. Cancer Ther. 2006. V. 5. № 1. P. 104 - 113.
  92. Willems A., Gauger K., Henrichs C., Harbeck N. Antibody therapy for breast cancer // Anticancer Res. 2005. V. 25 (3A). P. 1483 - 1489.
  93. Yakes F.M., Chinratanalab W., Ritter C.A. et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action // Cancer Res. 2002. V. 62. № 14. P. 4132 - 4141.
  94. Yuste L., Montero J.C., Esparis-Ogando A., Pandiella A. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin // Cancer Res. 2005. V. 65. № 15. P. 6801 - 6810.